Natera/$NTRA
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Natera
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Ticker
$NTRA
Sector
Primary listing
Employees
4,429
Headquarters
Website
Natera Metrics
BasicAdvanced
$27B
-
-$1.92
1.68
-
Price and volume
Market cap
$27B
Beta
1.68
52-week high
$199.21
52-week low
$120.80
Average daily volume
1.2M
Financial strength
Current ratio
3.72
Quick ratio
3.444
Long term debt to equity
8.244
Total debt to equity
14.691
Interest coverage (TTM)
-45.40%
Profitability
EBITDA (TTM)
-262.039
Gross margin (TTM)
62.86%
Net profit margin (TTM)
-12.89%
Operating margin (TTM)
-14.95%
Effective tax rate (TTM)
0.07%
Revenue per employee (TTM)
$440,000
Management effectiveness
Return on assets (TTM)
-11.21%
Return on equity (TTM)
-24.32%
Valuation
Price to revenue (TTM)
13.33
Price to book
21.83
Price to tangible book (TTM)
21.83
Price to free cash flow (TTM)
250.414
Free cash flow yield (TTM)
0.40%
Free cash flow per share (TTM)
0.794
Growth
Revenue change (TTM)
44.38%
Earnings per share change (TTM)
-21.26%
3-year revenue growth (CAGR)
39.51%
10-year revenue growth (CAGR)
26.40%
3-year earnings per share growth (CAGR)
-31.80%
10-year earnings per share growth (CAGR)
-9.92%
What the Analysts think about Natera
Analyst ratings (Buy, Hold, Sell) for Natera stock.
Bulls say / Bears say
Natera’s Q2 2025 revenue rose 32.2% year over year to $546.6 million, beating analyst estimates and leading management to raise its 2025 revenue outlook by $80 million.
Natera presented data from more than 25 Signatera™ studies involving nearly 25,000 patients at the 2025 ASCO Annual Meeting, highlighting strong clinical validation across multiple cancer types.
In Q2 2025, Natera delivered positive cash flow of $24.3 million, its second straight quarter of free cash flow, increasing its financial flexibility.
Guardant Health filed a trade secret theft lawsuit against Natera in February 2025, seeking to block use of its confidential files and exposing Natera to potential legal liabilities.
Competition in the MRD and early cancer detection market has intensified, with new multi-cancer blood tests launched by Exact Sciences, Grail, and Guardant, increasing pressure on Natera’s market share and pricing power.
Despite strong revenue growth, Natera posted a GAAP loss of $0.74 per share in Q2 2025, as higher operating expenses and legal accruals offset margin improvements.
Data summarised monthly by Lightyear AI. Last updated on 3 Nov 2025.
Natera Financial Performance
Revenues and expenses
Natera Earnings Performance
Company profitability
Natera News
AllArticlesVideos
Natera Announces Expansion to 20 Genes for its Fetal Focus™ Single-Gene NIPT
Business Wire3 days ago
Halper Sadeh LLC Encourages Natera Inc. Shareholders to Contact the Firm to Discuss Their Rights
Business Wire1 week ago
Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients
Business Wire2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Natera stock?
Natera (NTRA) has a market cap of $27B as of November 03, 2025.
What is the P/E ratio for Natera stock?
The price to earnings (P/E) ratio for Natera (NTRA) stock is 0 as of November 03, 2025.
Does Natera stock pay dividends?
No, Natera (NTRA) stock does not pay dividends to its shareholders as of November 03, 2025.
When is the next Natera dividend payment date?
Natera (NTRA) stock does not pay dividends to its shareholders.
What is the beta indicator for Natera?
Natera (NTRA) has a beta rating of 1.68. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.